Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade F 29.505 -3.42% -1.05
MYL closed down 4.05 percent on Friday, December 7, 2018, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MYL trend table...

Date Alert Name Type % Chg
Dec 7 Below Lower BB Weakness -3.42%
Dec 7 Down 3 Days in a Row Weakness -3.42%
Dec 7 Lower Bollinger Band Touch Weakness -3.42%
Dec 7 Oversold Stochastic Weakness -3.42%
Dec 6 Stochastic Reached Oversold Weakness -7.33%
Dec 6 Gapped Down Weakness -7.33%
Dec 6 Lower Bollinger Band Touch Weakness -7.33%
Dec 6 Oversold Stochastic Weakness -7.33%
Dec 4 50 DMA Resistance Bearish -10.48%
Dec 4 Expansion Pivot Sell Setup Bearish Swing Setup -10.48%

Older signals for MYL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 47.82
52 Week Low 30.33
Average Volume 5,499,576
200-Day Moving Average 37.6147
50-Day Moving Average 33.8016
20-Day Moving Average 34.1865
10-Day Moving Average 33.184
Average True Range 1.2196
ADX 21.8
+DI 14.2328
-DI 31.9534
Chandelier Exit (Long, 3 ATRs ) 33.9012
Chandelier Exit (Short, 3 ATRs ) 34.1088
Upper Bollinger Band 37.2158
Lower Bollinger Band 31.1572
Percent B (%b) -0.1
BandWidth 17.7222
MACD Line -0.5103
MACD Signal Line -0.1753
MACD Histogram -0.3349
Fundamentals Value
Market Cap 16.39 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 24.64
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.88
Resistance 3 (R3) 33.10 32.55 32.49
Resistance 2 (R2) 32.55 31.96 32.44 32.36
Resistance 1 (R1) 31.55 31.59 31.28 31.33 32.23
Pivot Point 31.00 31.00 30.86 30.89 31.00
Support 1 (S1) 30.00 30.41 29.73 29.78 28.87
Support 2 (S2) 29.45 30.04 29.34 28.74
Support 3 (S3) 28.45 29.45 28.61
Support 4 (S4) 28.23